Omeros seeks orphan-drug status for rare disease drug

04/22/2013 | Pharmaceutical Business Review Online

Omeros submitted an application to the FDA seeking orphan-drug designation for OMS721, an investigational drug for atypical hemolytic uremic syndrome. The drug, which targets the lectin pathway of the complement system, is formulated for self-administration through subcutaneous injection. The firm plans to apply for a similar designation in Europe and to initiate clinical studies in the summer.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC